TAK: 20-F financial filing

tak-20260331 As filed with the Securities and Exchange Commission on June 17, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ___________________________________________________________ ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31 , 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001-38757 ___________________________________________________________ Takeda Yakuhin Kogyo Kabushiki Kaisha (Exact name of registrant as specified in its charter) ___________________________________________________________ Takeda Pharmaceutical Company Limited (Translation of registrant’s name into English) ___________________________________________________________ Japan 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku , Tokyo 103-8668 , Japan (Jurisdiction of incorporation or organization) (Address of principal executive offices) Milano Furuta 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku , Tokyo 103-8668 , Japan Tel: +81 3 3278-2306 Fax: +81 3 3278-2268 Email: Global.External.Reporting@takeda.com (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) ___________________________________________________________ Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbols Name of Each Exchange On Whic